The Online Investor
Athenex Inc (ATNX)

Athenex is a biopharmaceutical company focused on the discovery, development and commercialization of products for the treatment of cancer. Co. manages its operations in two reportable segments: Oncology Innovation Platform, which is focused on the research and development of its proprietary drugs and; Commercial Platform, which focused on the sales and marketing of drugs and the market development of its proprietary drugs. Co. is also continuing certain studies of oral paclitaxel and encequidar, the active product candidate using its Orascovery technology, based on a P-glycoprotein pump inhibitor.
Company Name: 
Athenex Inc
Website: 
www.athenex.com
Sector: 
Biotechnology
Quotes delayed 20 minutes

Email EnvelopeFree ATNX Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Hold (2.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)

Analysts' Target Price:
ATNX Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Athenex Inc (ATNX) Page | The Online Investor Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.